Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,623 across all filing types
Latest filing 2025-08-06 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025
Regulatory Filings Classification · 92% confidence The document is an HKEX FF301 ‘Monthly Return for Equity Issuer and Hong Kong Depositary Receipts’ under Chapter 19B, detailing routine monthly movements in authorised share capital, issued shares, share options, etc. It is a regulatory compliance filing rather than an AGM presentation, earnings release, or capital-raising announcement. It does not announce a specific dividend, share issue, or M&A, nor is it a transcript, annual report, or interim report. Hence, it fits the fallback category ‘Regulatory Filings’ (RNS).
2025-08-06 English
Monthly Return of Equity Issuer on Movement in Securities for the month ended 31 July 2025
Regulatory Filings Classification · 85% confidence The document is a routine monthly return (Form FF301) filed with the Hong Kong Stock Exchange detailing movements in authorized/registered share capital, issued shares, treasury shares, and other securities. It is not announcing a one-off transaction or report publication but is a regular regulatory compliance filing under the Listing Rules. This falls under the general “Regulatory Filings” category.
2025-08-01 English
ARTICLES OF ASSOCIATION
Governance Information Classification · 93% confidence The document is the full Articles of Association (the company’s constitution/by-laws) of RemeGen Co., Ltd., detailing its internal rules, governance structure, shareholder meeting procedures, board composition, and related corporate governance provisions. This is not an AGM presentation or financial report, but rather a governance information document. Therefore, it fits the Governance Information category.
2025-07-31 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-07-31 English
POLL RESULTS OF THE 2025 SECOND CLASS MEETING OF H SHAREHOLDERS
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an announcement of the poll (voting) results at an H Share Class Meeting, detailing the number of votes for, against, and abstentions on special resolutions and confirming that the resolutions were passed. It does not present a full report but discloses the official shareholder vote outcomes. Therefore, it falls under Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2025-07-31 English
PROXY FORM FOR USE AT THE 2025 SECOND CLASS MEETING OF H SHAREHOLDERS
Proxy Solicitation & Information Statement Classification · 98% confidence The document is a proxy form for the 2025 second class meeting of H shareholders, including instructions for appointing a proxy and voting on resolutions. This form is part of proxy solicitation materials sent to shareholders to request votes for corporate meetings, fitting the definition of a Proxy Solicitation & Information Statement (PSI).
2025-07-14 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.